Actively Recruiting
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
Led by Genentech, Inc. · Updated on 2026-04-17
24
Participants Needed
1
Research Sites
71 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the pharmacodynamic (PD) effects of vixarelimab in the gut of participants with active moderate to severe ulcerative colitis (UC).
CONDITIONS
Official Title
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of ulcerative colitis established at least 3 months ago
- Moderately to severely active ulcerative colitis
- Participants must meet criteria for either advanced therapy failure or conventional therapy failure
You will not qualify if you...
- Diagnosis of Crohn's disease or indeterminate colitis
- Suspicion of ischemic colitis, radiation colitis, microscopic colitis, or infectious colitis
- Prior colectomy
- Prior treatment with systemic janus kinase (JAK) inhibitors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Charité Research Organisation GmbH
Berlin, Germany, 10117
Actively Recruiting
Research Team
R
Reference Study ID Number: GA45735 https://forpatients.roche.com/
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here